Antibody–drug conjugate combinations take center stage in recent urothelial cancer advancements

This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, overall survival nearly doubled in patients assigned to disitamab vedotin plus toripalimab in comparison with those assigned to chemotherapy. In addition, nine‐year data show a sustained benefit of nivolumab in patients with high‐risk resected melanoma, and zanzalintinib plus atezolizumab is the first immunotherapy regimen to benefit patients with metastatic colorectal cancer.